Rare Tumors

Scope & Guideline

Transforming the landscape of rare tumor research.

Introduction

Explore the comprehensive scope of Rare Tumors through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore Rare Tumors in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN2036-3605
PublisherSAGE PUBLICATIONS LTD
Support Open AccessYes
CountryItaly
TypeJournal
Convergefrom 2010 to 2024
AbbreviationRARE TUMORS / Rare Tumors
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND

Aims and Scopes

The journal 'Rare Tumors' focuses on the publication of original research and case reports that delve into the unique characteristics, management strategies, and outcomes of rare tumors across various demographics. It aims to foster knowledge and understanding of less common malignancies, providing a platform for sharing clinical experiences that can influence treatment approaches and improve patient outcomes.
  1. Clinical Characteristics and Outcomes:
    The journal emphasizes the clinical presentation, characteristics, and treatment outcomes of rare tumors, providing insights that can guide clinical practice and improve patient management.
  2. Case Reports and Literature Reviews:
    A significant portion of the journal is dedicated to detailed case reports and literature reviews, which highlight unique and rare tumor presentations, diagnostic challenges, and therapeutic approaches.
  3. Multidisciplinary Approaches to Rare Tumors:
    The journal encourages discussions on multidisciplinary treatment strategies involving surgery, chemotherapy, radiation, and emerging therapies for managing rare tumors.
  4. Emerging Therapies and Innovations:
    It explores novel therapeutic options and advancements in the management of rare tumors, including the use of immunotherapies and targeted therapies.
  5. Global Perspectives on Rare Tumors:
    The journal features studies from various geographical locations, allowing for a broader understanding of rare tumors in diverse populations and healthcare settings.
Recent publications in 'Rare Tumors' have highlighted a number of trending and emerging themes that reflect the evolving landscape of rare tumor research. These themes indicate a shift towards more personalized medicine, innovative therapies, and comprehensive patient management strategies.
  1. Innovative Immunotherapies:
    There is a growing emphasis on the exploration of immunotherapy as a treatment modality for various rare tumors, reflecting a broader trend in oncology towards personalized and targeted treatment options.
  2. Psychosocial and Quality of Life Studies:
    Recent papers are increasingly addressing the psychosocial aspects and quality of life of patients with rare tumors, highlighting the importance of holistic patient care beyond just clinical outcomes.
  3. Multidisciplinary Treatment Approaches:
    The trend towards collaborative, multidisciplinary treatment strategies is evident, with more studies focusing on how combined efforts from different specialties can enhance patient outcomes for rare tumors.
  4. Genetic and Molecular Characterization:
    There is an emerging focus on the genetic and molecular profiling of rare tumors, contributing to a better understanding of tumor behavior and potential targeted therapies.
  5. Global Health Perspectives:
    An increase in studies that consider global health perspectives on rare tumors, including case reports from diverse geographical regions, is evident, promoting a more inclusive understanding of these malignancies.

Declining or Waning

While 'Rare Tumors' continues to focus on various aspects of rare malignancies, certain themes have shown a decline in prominence over recent years. These waning areas may reflect shifts in research priorities or the consolidation of knowledge in previously underexplored topics.
  1. General Tumor Biology Studies:
    There has been a noticeable decrease in publications focusing solely on the basic biology of rare tumors, as the journal shifts towards more clinically relevant case studies and treatment outcomes.
  2. Traditional Chemotherapy Protocols:
    The frequency of papers discussing traditional chemotherapy protocols for rare tumors is declining, possibly due to the rise of targeted therapies and immunotherapies that are gaining prominence in treatment discussions.
  3. Epidemiological Studies of Rare Tumors:
    Fewer epidemiological studies are being published, suggesting a waning interest in the statistical analysis of rare tumor incidence and prevalence, which may have been overshadowed by more pressing clinical insights and therapeutic innovations.

Similar Journals

Acta Oto-Laryngologica Case Reports

Advancing Knowledge in Otolaryngology Through Unique Case Reports
Publisher: TAYLOR & FRANCIS LTDISSN: 2377-2484Frequency: 1 issue/year

Acta Oto-Laryngologica Case Reports, published by Taylor & Francis Ltd, is an esteemed open-access journal dedicated to the dissemination of high-quality case reports in the field of otolaryngology. Since its inception in 2016, this journal has been a vital platform for researchers and clinicians to share unique clinical insights and advancements related to ear, nose, and throat disorders. With an ISSN of 2377-2484, it provides unparalleled access to the latest findings, facilitating collaboration and innovation among professionals in otolaryngology. The journal's commitment to open-access publishing ensures that critical research is freely available to a global audience, enhancing the visibility and impact of its contributors' work. Researchers, practitioners, and students in the medical field will find valuable resources and case studies that not only contribute to professional development but also address current challenges in patient care.

Journal of Bone Oncology

Connecting Knowledge for Better Bone Oncology Outcomes
Publisher: ELSEVIERISSN: Frequency: 4 issues/year

Journal of Bone Oncology, published by ELSEVIER, is a pivotal open access journal that has been advancing the field of oncology since its inception in 2012. Focused on the intricate relationship between bone-related malignancies and therapeutic advancements, this journal addresses critical issues in bone oncology, including novel treatments, diagnostic methodologies, and translational research. With a commendable impact factor reflecting its scholarly contributions and ranking in the Q2 category of oncology journals (2023), the Journal of Bone Oncology is recognized within the top 67th percentile across Scopus rankings, showcasing its relevance and quality in the medical oncology landscape. Available in open access, the journal promotes widespread dissemination of knowledge, ensuring that researchers, professionals, and students can access groundbreaking research that informs clinical practices and enhances patient outcomes. Located in Germany and targeting a global audience, the journal’s wealth of resources serves as an essential platform for fostering collaboration and innovation in the oncology community.

Clinical Genitourinary Cancer

Pioneering discoveries for improved patient outcomes.
Publisher: CIG MEDIA GROUP, LPISSN: 1558-7673Frequency: 6 issues/year

Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.

Endocrinology Diabetes and Metabolism Case Reports

Elevating Standards in Endocrine Research and Care
Publisher: BIOSCIENTIFICA LTDISSN: Frequency: 1 issue/year

Endocrinology Diabetes and Metabolism Case Reports, published by BIOSCIENTIFICA LTD, stands as a pivotal forum for sharing significant advancements and clinical case studies in the fields of endocrinology, diabetes, and metabolism. With an Open Access model initiated in 2013, this journal encourages the widespread dissemination and accessibility of research findings, promoting collaboration and innovation among scholars and healthcare professionals. Based in the United Kingdom, the journal features a focus on practical applications and unique case reporting that enriches the clinical understanding and management of complex endocrine disorders. Though currently it's ranked in the Q3 category for both Endocrinology, Diabetes and Metabolism and Internal Medicine, its ongoing commitment to quality and impact in clinical research makes it a valuable resource for researchers, professionals, and students alike, contributing to the advancement of knowledge in this critical medical domain.

Leukemia Research Reports

Leading the charge in blood disorder research.
Publisher: ELSEVIER ADVANCED TECHNOLOGYISSN: 2213-0489Frequency: 2 issues/year

Leukemia Research Reports, published by Elsevier Advanced Technology, is a prominent open-access journal dedicated to the latest advancements in the field of hematology and oncology. Since its launch in 2012, this journal has been a vital resource for researchers, healthcare professionals, and students aiming to disseminate and access high-quality research articles focused on various aspects of leukemia and related blood disorders. With an impact factor indicative of its significance in the field, Leukemia Research Reports currently holds a Q3 quartile ranking in both Hematology and Oncology, and is included in key databases such as Scopus. The journal not only embraces a commitment to open access, ensuring that research is freely available, but also actively promotes collaborations that strive to enhance our understanding and treatment of leukemia. Based in the United Kingdom, this journal continues to play a crucial role in fostering innovation and knowledge sharing within the medical community.

SAGE Open Medical Case Reports

Sharing Unique Clinical Experiences for Better Care
Publisher: SAGE PUBLICATIONS INCISSN: 2050-313XFrequency: 1 issue/year

SAGE Open Medical Case Reports, published by SAGE Publications Inc, is a pioneering open-access journal dedicated to the rapid dissemination of medical case reports that significantly contribute to clinical knowledge and practice. Since its launch in 2013, this journal has become a valuable resource for healthcare professionals, researchers, and students in the field of medicine, facilitating the exchange of unique clinical experiences from around the globe. While the journal is categorized as Q4 in the Medicine (miscellaneous) quartile and holds a Scopus rank of 423 out of 636 in the General Medicine category, the accessibility of its content underscores its commitment to enhancing medical education and informing practice. With no subscription barriers, it supports the sharing of critical insights appropriate to a diverse audience, thereby fostering a culture of innovation and collaboration in healthcare.

Blood and Lymphatic Cancer-Targets and Therapy

Pioneering Insights into Blood and Lymphatic Cancer
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-9889Frequency: 1 issue/year

Blood and Lymphatic Cancer-Targets and Therapy, published by DOVE MEDICAL PRESS LTD, is a vital open-access journal that has been disseminating crucial research and findings in the field of hematology and oncology since 2011. With its ISSN 1179-9889, this journal focuses on the latest therapeutic targets and innovative treatment strategies for blood and lymphatic cancers, contributing significantly to the advancement of knowledge and practice in this specialized area. Designed for researchers, healthcare professionals, and students alike, Blood and Lymphatic Cancer-Targets and Therapy aims to foster a deeper understanding of cancer biology and promote collaborative efforts leading to novel therapeutic interventions. The open-access model ensures that research findings are readily accessible to a global audience, underscoring the journal's commitment to enhancing patient care and fostering educational growth in the cancer domain.

AME Case Reports

Fostering Scholarly Exchange for Better Patient Outcomes
Publisher: AME PUBLISHING COMPANYISSN: 2523-1995Frequency: 4 issues/year

AME Case Reports, published by AME PUBLISHING COMPANY, is a peer-reviewed open-access journal dedicated to the dissemination of high-quality clinical case reports across various medical disciplines. With an expanding focus on innovative medical practices and clinical experiences, this journal serves as an essential platform for healthcare professionals, researchers, and medical students to share significant findings and insights that contribute to evidence-based practices. Although specific metrics such as impact factors and H-index are not currently available, the journal's commitment to academic rigor and accessibility fosters an environment for scholarly exchange and professional development. The publication facilitates immediate access to important case studies that may inform clinical decisions and improve patient care. In an era where sharing specialized knowledge is paramount, AME Case Reports stands as a vital resource for those involved in the medical community worldwide.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Pioneering critical insights in oncology and hematology.
Publisher: ELSEVIER SCIENCE INCISSN: 1040-8428Frequency: 12 issues/year

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, published by Elsevier Science Inc, stands at the forefront of the medical literature dedicated to advancing our understanding of cancer and blood disorders. With its ISSN 1040-8428 and E-ISSN 1879-0461, this prestigious journal boasts an impressive impact factor, reflecting its significance in the fields of Geriatrics, Hematology, and Oncology. Notably, it has achieved the distinction of being ranked in the top quartile (Q1) for these categories as of 2023, with Scopus rankings placing it in the 93rd percentile in Geriatrics and Gerontology, 87th in Oncology, and 85th in Hematology. Since its inception in 1983 and continuing until 2024, the journal serves as a critical resource for researchers, medical professionals, and students alike, aiming to publish high-quality, peer-reviewed articles that facilitate knowledge exchange and promote innovation in clinical practices and therapeutic strategies. While the journal is not open access, it remains widely accessible through various academic institutions, ensuring that vital research findings reach those who need them most.

International Cancer Conference Journal

Fostering Collaboration for a Cancer-Free Future
Publisher: SPRINGER INT PUBL AGISSN: 2192-3183Frequency: 4 issues/year

International Cancer Conference Journal, published by Springer International Publishing AG, serves as a pivotal platform for the dissemination of cutting-edge research in the field of oncology. With a commitment to advancing the understanding, prevention, and treatment of cancer, this journal offers a forum for the presentation of innovative studies, clinical trials, and comprehensive reviews that cater to the needs of researchers, healthcare professionals, and students alike. Although currently not open access, the journal is dedicated to fostering collaboration and knowledge sharing within the cancer research community. The ISSN for this journal is 2192-3183, ensuring its listing within prominent academic databases for enhanced visibility. Hailing from Switzerland, the journal aspires to impact the global dialogue on cancer through rigorous peer-reviewed articles and special conference proceedings, making it an essential resource for those dedicated to the fight against cancer.